Tacrolimus: In heart transplant recipients

Drugs

Volumn 66, Issue 17, 2006, Pages 2269-2279

  McCormack, Paul L ^a   Keating, Gillian M ^b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INSULIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; POTASSIUM; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE KIDNEY FAILURE; ADJUVANT THERAPY; ANEMIA; AREA UNDER THE CURVE; CANCER; CARDIOVASCULAR DISEASE; CHOLELITHIASIS; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FOLLOW UP; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GRAFT REJECTION; HEART TRANSPLANTATION; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INCIDENCE; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LEUKOPENIA; LONG TERM CARE; MICROEMULSION; NEUROLOGIC DISEASE; POTASSIUM BLOOD LEVEL; QUALITY OF LIFE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREMOR; UNSPECIFIED SIDE EFFECT; WOUND HEALING;

CLINICAL TRIALS; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TACROLIMUS;

EID: 33845318883     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666170-00010     Document Type: Review

References (44)

1. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult heart transplant report - 2005. J Heart Lung Transplant 2005 Aug; 24 (8): 945-55
2. Scott LJ, McKeage K, Keam SJ, et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003; 63 (12): 1247-97
3. Astellas Pharma Inc. Prograf now approved for prophylaxis use in heart transplantation across Europe [online]. Available from URL: http://www.astellas. com [Accessed 2006 Apr 24]
4. Astellas Pharma US. Astellas receives FDA approval of Prograf® (tacrolimus) for use in heart transplant recipients [online]. Available from URL: http://www.astellas.com [Accessed 2006 Apr 3]
5. Astellas Pharma Ltd. Prograf (tacrolimus) hard capsules: summary of product characteristics [online]. Available from URL: http://emc.medicines.org. uk [Accessed 2006 Aug 7]
6. Reichenspurner H. Overview of tacrolimus-based immunosuppression after heart or lung transplantation. J Heart Lung Transplant 2005 Feb; 24 (2): 119-30
7. Astellas Pharma US. Prograf® (tacrolimus capsules/injection) US prescribing information [online]. Available from URL: http://www.astellas.us/ docs/prograf.pdf [Accessed 2006 Jul 24]
8. Jiang H, Yang X, Soriano RN, et al. Distinct patterns of cytokine gene suppression by the equivalent effective doses of cyclosporine and tacrolimus in rat heart allografts. Immunobiology 2000 Sep; 202 (3): 280-92
9. Ḧokl J, Cerny J, Ondrasek J, et al. Apoptosis of peripheral T cells in stable recipients with Neoral or tacrolimus immunosuppression after heart transplantation. Scripta Medica (BRNO) 2003; 76 (6): 379-84
10. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43 (10): 623-53
11. White M, Haddad H, Leblanc MH, et al. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion. J Heart Lung Transplant 2005 Jul 1; 24 (7): 798-809
12. van Riemsdijk IC, Baan CC, Balk AH, et al. Improvement of cardiovascular risk factors in heart transplant recipients after conversion from cyclosporine to tacrolimus: a role of the TGF-beta system. Transplant Proc 2002 Aug; 34 (5): 1864-5
13. Uber PA, Mehra MR, Vivekananthan N, et al. The differential metabolic impact of tacrolimus and cyclosporine immunosuppression in black heart transplant recipients: hyperlipidemia, hypertension and hyperglycemia [abstract no. 127]. J Heart Lung Transplant 2001 Feb; 20 (2): 192
14. Johnson KA, Jenco KK, Estrada T, et al. Effect of tacrolimus (FK-506) on magnesium and potassium balance in heart transplant patients [abstract no. 198]. Pharmacotherapy 1994 May; 14 (3): 377
15. Petrakopoulou P, Anthopoulou L, Muscholl M, et al. Coronary endothelial vasomotor function and vascular remodeling in heart transplant recipients randomized for tacrolimus or cyclosporine immunosuppression. J Am Coll Cardiol 2006 Apr 18; 47 (8): 1622-9
16. Undre NA, Meiser BM, Uberfuhr P, et al. Pharmacokinetics of tacrolimus (FK506) in primary orthotopic heart transplant patients. Transplant Proc 1998 Jun; 30: 1112-5
17. Regazzi MB, Rinaldi M, Molinaro M, et al. Clinical pharmacokinetics of tacrolimus in heart transplant recipients. Ther Drug Monit 1999 Feb; 21: 2-7
18. Undre NA, Stevenson PJ. Pharmacokinetics of tacrolimus in heart transplantation. Transplant Proc 2002 Aug; 34 (5): 1836-8
19. Sgrosso JL, Araujo GL, Vázquez MC. Tacrolimus pharmacokinetics in heart transplant. Transplant Proc 2002 Feb; 34: 142-3
20. Aumente Rubio MD, Arizón del Prado JM, López Malo de Molina MD, et al. Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring. Transplant Proc 2003 Aug; 35 (5): 1988-91
21. Molinaro M, Regazzi MB, Pasquino S, et al. Pharmacokinetics of tacrolimus during the early phase after heart transplantation. Transplant Proc 2001 May; 33: 2386-9
22. Aidong W, Zhenjie C, Tong L, et al. Therapeutic drug monitoring of tacrolimus in early stage after heart transplantation. Transplant Proc 2004 Oct; 36 (8): 2388-9
23. Zheng HX, Webber S, Zeevi A, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 2003 Apr; 3: 477-83
24. Uber PA, Mehra MR, Scott RL, et al. Ethnic disparities in the pharmacologic characteristics of tacrolimus in heart transplantation. Transplant Proc 2001 Feb; 33: 1581-2
25. Zucker K, Tsaroucha A, Olson L, et al. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 1999 Feb; 21 (1): 35-43
26. Kobashigawa JA, Patel J, Furukawa H, et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant 2006 Apr; 25 (4): 434-9
27. Podesser BK, Rinaldi M, Yona NA, et al. Comparison of low and high initial tacrolimus dosing in primary heart transplant recipients: a prospective European multicenter study. Transplantation 2005 Jan 15; 79 (1): 65-71
28. Meiser BM, Groetzner J, Kaczmarek I, et al. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? Transplantation 2004 Aug 27; 78 (4): 591-8
29. Grimm M, Rinaldi M, Yonan NA, et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients: a large European trial. Am J Transplant 2006 Jun; 6 (6): 1387-97
30. Reichart B, Meiser B, Vigano M, et al. European multicenter tacrolimus (FK506) heart pilot study: one-year results. European Tacrolimus Multicenter Heart Study Group. J Heart Lung Transplant 1998 Aug; 17 (8): 775-81
31. Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006 Jun; 6 (6): 1377-86
32. Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999 Apr; 18 (4): 336-45
33. Pollock-BarZiv SM, Dipchand AI, McCrindle BW, et al. Randomized clinical trial of tacrolimus- vs cyclosporine-based immunosuppression in pediatric heart transplantation: preliminary results at 15-month follow-up. J Heart Lung Transplant 2005 Feb; 24 (2): 190-4
34. Armitage JM, Kormos RL, Morita S, et al. Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. Ann Thorac Surg 1992 Aug; 54: 205-11
35. Mehra MR, Uber PA, Scott RL, et al. Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression. Transplantation 2002 Dec 15; 74 (11): 1568-73
36. Armitage JM, Fricker FJ, Del Nido P, et al. The clinical trial of FK 506 as primary and rescue immunosuppression in pediatric cardiac transplantation. Transplant Proc 1991 Dec; 23 (6): 3058-60
37. Eisen HJ, Hobbs RE, Davis SF, et al. Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine - results at 24 months after transplantation. Tansplantation 2001 Jan; 71 (1): 70-8
38. Pham SM, Kormos RL, Hattler BG, et al. A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg 1996 Apr; 111: 764-72
39. Billingham ME, Cary NRB, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. International Society for Heart Transplantation. J Heart Transplant 1990; 9 (6): 587-93
40. Kaczmarek I, Ertl B, Schmauss D, et al. Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil. J Heart Lung Transplant 2006 May; 25 (5): 550-6
41. Steinbüchel Nv, Limm H, Leopold C, et al. Assessment of health-related quality-of-life in patients after heart transplantation under therapy with tacrolimus or cyclosporine. Transpl Int 2000; 13 Suppl. 1: S609-14
42. Dew MA, Harris RC, Simmons RG, et al. Quality-of-life advantages of FK 506 vs conventional immunosuppressive drug therapy in cardiac transplantation. Transplant Proc 1991 Dec; 23: 3061-4
43. English RF, Pophal SA, Bacanu SA, et al. Long-term comparison of tacrolimus- and cyclosporine-induced nephrotoxicity in pediatric heart-transplant recipients. Am J Transplant 2002 Sep; 2: 769-73
44. Crespo-Leiro MG. Tacrolimus in heart transplantation. Transplant Proc 2003 Aug; 35 (5): 1981-3